Model PAP-0094 -BendaMustine Hydrochloride
FromCD Formulation
Bendamustine hydrochloride monotherapy or combination therapy has been designated by European and American clinical guidelines as a first - or second-line treatment option for a variety of hematological malignancies.
Most popular related searches
active pharmaceutical ingredient
chronic lymphocytic leukemia
pharmaceutical ingredient
hematologic malignancies
lymphocytic leukemia
pharmaceuticals
hematologic
hematology
hematology product
leukemia
- Product Name: BendaMustine Hydrochloride
- Cat.No.: PAP-0094
- Particle Size: Inquiry
Molecular Formula
C16H22Cl3N3O2
Appearance
Powder
Description
Bendamustine hydrochloride monotherapy or combination therapy has been designated by European and American clinical guidelines as a first - or second-line treatment option for a variety of hematological malignancies
CAS Number
3543-75-7
Solubility
H2O: >30mg/mL
Storage
room temp
Applications
Treatment of Chronic Lymphocytic Leukemia (CLL)
Melting Point
149-151°C
EC Number
631-540-0
Molecular Weight (g/mol)
394.72
Physical State
powder
Color
off-white